AMBEV S.A. current report, Q2 FY2023

Business Context and Reporting Period

This Form 6-K filing by AMBEV S.A. reports a corporate action approved by the Board of Directors on April 25, 2023. The filing pertains to the issuance of new common shares resulting from the exercise of stock options under the Company's 2023 Stock Option Plan.

Key Financial Metrics

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes.

Metric Value
Capital Increase Amount BRL 47,411,436.63
New Capital Stock (Total) BRL 58,177,928,601.85
Number of New Shares Issued 3,616,433 common shares
Issuance Price Per Share BRL 13.11

Material Changes

The primary material change is the increase in the Company's capital stock and the number of outstanding shares due to the exercise of stock options by certain beneficiaries. This action was executed pursuant to the "First Program for the year of 2023 of the Company's Stock Option Plan."

Guidance, Outlook, and Risks

The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural notice regarding the capital increase.

Investor Verification Checklist

  • Verify the total number of outstanding shares post-issuance to confirm the dilution impact.
  • Confirm the total capital stock value of BRL 58,177,928,601.85 in subsequent filings.
  • Review the terms of the "First Program for the year of 2023 of the Company's Stock Option Plan" for details on remaining option grants.
  • Note that the potential dilution is minimal, calculated at 0.022961% regarding share count and 0.081560% regarding capital stock.